Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled dose-ranging study of SAR443765 in adults with moderate-to-severe asthma
MOH_2024-01-16_013192Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Dec 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lunsekimig in asthma (5 arms), sponsored by Sanofi. Primary endpoint: Primary endpoint not reported. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2024-01-16_013192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-16_013192.